BRAF突变型非小细胞肺癌免疫检查点 抑制剂治疗进展
Zhongguo fei ai za zhi = Chinese journal of lung cancer（2019）
Abstract
在非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中,约2％-4％有BRAF基因突变,该型肿瘤恶性程度高、化疗有效率低、预后差.尽管BRAF抑制剂及MEK抑制剂联合治疗在BRAF V600E突变的晚期NSCLC患者中成效显著,已被写入美国国家综合癌症网络(National Comprehensive Cancer Network,NCCN)指南,但两药联合副作用发生率高,耐药之后尚无有效治疗策略,且针对非V600E突变患者仍缺乏靶向治疗方案.本文将针对BRAF突变型NSCLC免疫标志物表达情况以及免疫检查点抑制剂(immune checkpoint inhibitor,ICI)疗效相关研究做一综述,为延长患者生存提供更多选择方案.
MoreTranslated text
Key words
Immune checkpoint inhibitor therapy,Lung neoplasms,V-raf murine sar-coma viral oncogene homolog B1
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined